文献速递神经肿瘤

VGLL融合定义一类新的脑实质内中枢神经系统神经鞘瘤

VGLL fusions define a new class of intraparenchymal central nervous system schwannoma.
PubMed 文献 · Neuro Oncol · 2025-01-01

研究对20例脑内神经鞘瘤样本进行组织学、RNA二代测序、DNA甲基化分型、拷贝数分析及单核RNA测序,临床与MRI资料按可得情况纳入。所有病例的DNA甲基化谱不同于其他中枢神经系统肿瘤及VGLL改变的周围神经鞘瘤,14/17例存在VGLL3或VGLL1融合。作者据此提出并定义一类新的良性肿瘤:VGLL改变的脑实质内中枢神经系统神经鞘瘤。

要点

  • 所有20例肿瘤的DNA甲基化谱均不同于其他中枢神经系统肿瘤和VGLL改变的周围神经鞘瘤。
  • 14/17例检出融合,其中CHD7::VGLL3为9/17例、EWSR1::VGLL1为5/17例。
  • 中位随访1.8年(范围3个月至9年)期间10例均未见肿瘤复发。

核心结论

  • 作者识别并定义了一类新的良性肿瘤,命名为VGLL改变的脑实质内中枢神经系统神经鞘瘤,其具有VGLL改变和特定DNA甲基化谱,组织学呈神经鞘瘤样,位于中枢神经系统,与既往分类的脑内神经鞘瘤相似。

研究设计与样本

  • 对20例肿瘤样本进行组织学、RNA二代测序、DNA甲基化分型、拷贝数分析和单核RNA测序(snRNA-seq)。
  • 收集年龄、性别和疾病进展等临床数据;有可用MRI系列时纳入分析。
  • 组织学复核可用的病例为13例(n=13)。

主要发现

  • 组织学复核可用的13例形态学均符合脑内神经鞘瘤,但胶质纤维酸性蛋白染色范围不同。
  • 所有20例的DNA甲基化谱均不同于其他中枢神经系统肿瘤,也不同于VGLL改变的周围神经鞘瘤。
  • 17例中14例存在VGLL3或VGLL1融合:CHD7::VGLL3为9/17例,EWSR1::VGLL1为5/17例。
  • 2例(2/17)经拷贝数分析也确认存在VGLL3融合。
  • MRI(n=4)显示边界清楚的结节状肿瘤,明显均匀强化,无弥散受限;肿瘤分布为上幕15例、下幕4例、脊髓1例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracerebral schwannomas are rare tumors resembling their peripheral nerve sheath counterparts but localized in the central nervous system (CNS). They are not classified as a separate tumor type in the 2021 World Health Organization classification. This study aimed to compile and characterize these rare neoplasms morphologically and molecularly. METHODS: We analyzed 20 tumor samples by histology, RNA next-generation sequencing, DNA-methylation profiling, copy number analyses, and single-nucleus RNA sequencing (snRNA-seq). Clinical data, including age, sex, and disease progression, were collected. Magnetic resonance imaging (MRI) series were included when available. RESULTS: All cases with tissue available for histology review (n = 13) were morphologically consistent with intracerebral schwannoma, but differed in their extent of glial fibrillary acidic protein staining. All (n = 20) shared DNA-methylation profiles distinct from other CNS tumors, as well as from Vestigial-like family (VGLL)-altered peripheral nerve sheath tumors. Most cases (n = 14/17) harbored fusions of either Vestigial-like family member 3 (VGLL3) or Vestigial-like Family member 1 (VGLL1) (CHD7::VGLL3 [n = 9/17] and EWSR1::VGLL1 [n = 5/17]). In 2 cases, the presence of a VGLL3 fusion was also confirmed by copy number analyses (n = 2/17). MRI (n = 4) showed well-defined, nodular tumors with strong, homogeneous enhancement and no diffusion restriction. Tumors were located throughout the neuroaxis (supratentorial [n = 15], infratentorial [n = 4], and spinal [n = 1]). snRNA-seq of a VGLL1-fused tumor indicated VGLL1 upregulation in 28.6% of tumor cells (n = 1). During a median follow-up of 1.8 years (range 3 months-9 years), none of the tumors recurred (n = 10). CONCLUSIONS: We identify and define a new benign tumor class, designated VGLL-altered intraparenchymal CNS schwannomas. These tumors feature VGLL alterations and a specific DNA-methylation profile, with schwannoma-like histopathology and CNS localization, akin to previously classified intracerebral schwannomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Schmid S, Mirchia K, Tietze A, et al. VGLL fusions define a new class of intraparenchymal central nervous system schwannoma. Neuro Oncol. 2025. PMID: 39713960. doi:10.1093/neuonc/noae269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。